Singapore-based biopharmaceutical company Tessa Therapeutics has raised an $80-million financing round led by Singapore state investor Temasek Holdings, EDBI, Karst Peak Capital, Heliconia Capital Management, Heritas and other investors.
Founded in 2001 by Dr. Malcolm Brenner, Andrew Khoo and Francis Chua, Tessa will use the proceeds to further advance its clinical pipeline and to bring new therapies, based on the company’s Virus-Specific T cell (VST) platform, into clinical trials.
Continue reading this premium story with a subscription to DealStreetAsia.Subscribe
Already a Subscriber? Log in
Contact us for corporate subscriptions at email@example.com